Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,446 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Alterations in Mitochondrial Function in Pulmonary Vascular Diseases.
Farha S, Asosingh K, Hassoun PM, Barnard J, Comhair S, Reichard A, Wanner N, Radeva M, Aldred MA, Beck GJ, Berman-Rosenzweig E, Borlaug BA, Finet JE, Frantz RP, Grunig G, Hemnes AR, Hill N, Horn EM, Jellis C, Leopold JA, Mehra R, Park MM, Rischard FP, Tang WHW, Erzurum SC; PVDOMICS Study Group. Farha S, et al. Among authors: hill n. Antioxid Redox Signal. 2024 Dec 10. doi: 10.1089/ars.2024.0557. Online ahead of print. Antioxid Redox Signal. 2024. PMID: 39655485
Prognostic Significance of Biomarkers in Pulmonary Arterial Hypertension.
Al-Naamani N, Palevsky HI, Lederer DJ, Horn EM, Mathai SC, Roberts KE, Tracy RP, Hassoun PM, Girgis RE, Shimbo D, Post WS, Kawut SM; ASA-STAT Study Group. Al-Naamani N, et al. Ann Am Thorac Soc. 2016 Jan;13(1):25-30. doi: 10.1513/AnnalsATS.201508-543OC. Ann Am Thorac Soc. 2016. PMID: 26501464 Free PMC article. Clinical Trial.
Seralutinib in adults with pulmonary arterial hypertension (TORREY): a randomised, double-blind, placebo-controlled phase 2 trial.
Frantz RP, McLaughlin VV, Sahay S, Escribano Subías P, Zolty RL, Benza RL, Channick RN, Chin KM, Hemnes AR, Howard LS, Sitbon O, Vachiéry JL, Zamanian RT, Cravets M, Roscigno RF, Mottola D, Osterhout R, Bruey JM, Elman E, Tompkins CA, Parsley E, Aranda R, Zisman LS, Ghofrani HA; TORREY Study Investigators. Frantz RP, et al. Lancet Respir Med. 2024 Jul;12(7):523-534. doi: 10.1016/S2213-2600(24)00072-9. Epub 2024 May 2. Lancet Respir Med. 2024. PMID: 38705167 Clinical Trial.
Pulmonary hypertension across the spectrum of left heart and lung disease.
Borlaug BA, Larive B, Frantz RP, Hassoun P, Hemnes A, Horn E, Leopold J, Rischard F, Berman-Rosenzweig E, Beck G, Erzurum S, Farha S, Finet JE, Highland KB, Jacob M, Jellis C, Mehra R, Renapurkar R, Singh H, Tang WHW, Vanderpool R, Wilcox J, Yu S, Hill N. Borlaug BA, et al. Among authors: hill n. Eur J Heart Fail. 2024 Jul;26(7):1642-1651. doi: 10.1002/ejhf.3302. Epub 2024 Jun 4. Eur J Heart Fail. 2024. PMID: 38837273
Non-invasive prediction of pulmonary vascular disease-related exercise intolerance and survival in non-group 1 pulmonary hypertension.
Reddy YNV, Dubrock H, Hassoun PM, Hemnes A, Horn E, Leopold JA, Rischard F, Rosenzweig EB, Hill NS, Erzurum SC, Beck GJ, Mathai SC, Mukherjee M, Tang WHW, Borlaug BA, Frantz RP; and the PVDOMICS Study Group. Reddy YNV, et al. Among authors: hill ns. Eur J Heart Fail. 2024 Nov;26(11):2323-2336. doi: 10.1002/ejhf.3396. Epub 2024 Jul 26. Eur J Heart Fail. 2024. PMID: 39058211
Clinical Implications of Pretest Probability of HFpEF on Outcomes in Precapillary Pulmonary Hypertension.
Reddy YNV, Frantz RP, Hassoun PM, Hemnes AR, Horn E, Leopold JA, Rischard F, Rosenzweig EB, Hill NS, Erzurum SC, Beck GJ, Finet JE, Jellis CL, Mathai SC, Tang WHW, Borlaug BA. Reddy YNV, et al. Among authors: hill ns. J Am Coll Cardiol. 2024 Nov 26;84(22):2196-2210. doi: 10.1016/j.jacc.2024.08.061. Epub 2024 Oct 23. J Am Coll Cardiol. 2024. PMID: 39453363
Defining Echocardiographic Degrees of Right Heart Size and Function in Pulmonary Vascular Disease from the PVDOMICS Study.
Mukherjee M, Mathai SC, Jellis C, Freed BH, Yanek LR, Agoglia H, Chiu C, Jani VP, Simpson CE, Brittain EL, Tang WHW, Park MM, Hemnes AR, Rosenzweig EB, Rischard FP, Frantz RP, Hassoun PM, Beck G, Hill NS, Erzurum S, Thomas JD, Kwon D, Leopold JA, Horn EM, Kim J; PVDOMICS Study Group. Mukherjee M, et al. Among authors: hill ns. Circ Cardiovasc Imaging. 2024 Oct;17(10):e017074. doi: 10.1161/circimaging.124.017074. Epub 2024 Oct 15. Circ Cardiovasc Imaging. 2024. PMID: 39691460
Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial.
White RJ, Jerjes-Sanchez C, Bohns Meyer GM, Pulido T, Sepulveda P, Wang KY, Grünig E, Hiremath S, Yu Z, Gangcheng Z, Yip WLJ, Zhang S, Khan A, Deng CQ, Grover R, Tapson VF; FREEDOM-EV Investigators. White RJ, et al. Am J Respir Crit Care Med. 2020 Mar 15;201(6):707-717. doi: 10.1164/rccm.201908-1640OC. Am J Respir Crit Care Med. 2020. PMID: 31765604 Free PMC article. Clinical Trial.
A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.
Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH, Koerner SK, Langleben D, Keller CA, Murali S, Uretsky BF, Clayton LM, Jöbsis MM, Blackburn SD, Shortino D, Crow JW; Primary Pulmonary Hypertension Study Group. Barst RJ, et al. N Engl J Med. 1996 Feb 1;334(5):296-301. doi: 10.1056/NEJM199602013340504. N Engl J Med. 1996. PMID: 8532025 Free article. Clinical Trial.
Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension.
Barst RJ, Oudiz RJ, Beardsworth A, Brundage BH, Simonneau G, Ghofrani HA, Sundin DP, Galiè N; Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group. Barst RJ, et al. J Heart Lung Transplant. 2011 Jun;30(6):632-43. doi: 10.1016/j.healun.2010.11.009. Epub 2011 Jan 21. J Heart Lung Transplant. 2011. PMID: 21256048 Clinical Trial.
1,446 results